Treatment Options for Transplant-Ineligible Multiple Myeloma

Video

Nina Shah, MD, discusses the current treatment options for treating patients with transplant-ineligible multiple myeloma.

Nina Shah, MD: For transplant-ineligible patients, we traditionally had been using things like bortezomib [Velcade], lenalidomide [Revlimid], and dexamethasone, or VRd light, with lenalidomide maintenance therapy and that’s a perfectly good combination to use. The most recent MAIA trial [NCT02252172] data that were presented at the European [Hematology Association] Congress really did solidify the role for daratumumab [Darzalex], lenalidomide, dexamethasone in patients who are transplant-ineligible because there’s both a PFS [progression-free survival] and an overall survival advantage. It sounds like there’s going to be some nice quality-of-life data to suggest that these people are doing better despite being on therapy for longer.

Related Videos
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Saad Usmani, MD, MBA, FACP, an expert on multiple myeloma
Donna Catamero, ANP-BC, OCN, CCRC, an expert on multiple myeloma
Experts on MM
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Experts on MM
A panel of 4 experts on multiple myeloma seated at a long table
Experts on MM
Related Content
Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.

CAR T-cell Therapy Remains Preferred Options for Relapsed/Refractory Multiple Myeloma

December 1st 2023
Article

Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

August 14th 2023
Podcast

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Experts in the field of multiple myeloma gathered to discuss treatment options, including bispecific antibodies, CAR T-cell therapy, and current and future FDA approvals for treatments.

Multiple Myeloma Experts Discuss Treatment Options and New Advances

November 24th 2023
Article

Experts in the field of multiple myeloma gathered to discuss treatment options, including bispecific antibodies, CAR T-cell therapy, and current and future FDA approvals for treatments.

Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.

Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023

August 7th 2023
Podcast

Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.

A panel of experts discusses the management of adverse effects including dysgeusia and infections among patients who received bispecific therapies for relapsed/refractory multiple myeloma in the context of a clinical case.

Managing Toxicity Following Bispecific Therapy in R/R Multiple Myeloma

November 23rd 2023
Article

A panel of experts discusses the management of adverse effects including dysgeusia and infections among patients who received bispecific therapies for relapsed/refractory multiple myeloma in the context of a clinical case.

Mayo Clinic Reviews Outpatient Techniques for Monitoring Post CAR T-Cell Therapy

Mayo Clinic Reviews Outpatient Techniques for Monitoring Post CAR T-Cell Therapy

November 21st 2023
Article

In a recent Training Academy, experts discussed how to incorporate bispecific antibodies into patients with multiple myeloma.